Zusammenfassung
Erst Mitte der neunziger Jahre ist das Interesse an Fragen der geschlechtsspezifischen Tumorpharmakologie erwacht. Die am weitesten fortgeschrittenen Studien betreffen pharmakokinetische Untersuchungen der Fluorpyrimidine sowie preliminäre Daten zur Pharmagenomik, wobei die meisten pharmakogenetischen Fragen bisher unbeantwortet blieben. Bei Betrachtung der Polymorphismen relevanter metabolische Enzyme wie Folatreduktase, Cytochrom P450 abhängigen Oxidasen und UDP-Glukuronyltransferase fällt auf, dass die Hypothesen die Fakten bei weitem überwiegen. Die zukünftige Strategie sollte daher sinnvollerweise darauf ausgerichtet sein, das geringe vorhandene Wissen im Rahmen klinischer Studien auf akzeptierte klinische Evidenz zu heben, um die Implementierung in die onkologische Therapie voranzutreiben.
Summary
Gender specific tumour pharmacology only started to awake interest in the mid-90s. The most advanced studies include gender specific fluoropyrimidine pharmacokinetics and basic levels of pharmacogenomics, but most pharmacogenetic questions have remained unanswered. Considering polymorphisms of relevant drug converting enzymes such as folate reductase, cytochrome P450 dependent oxidases, and UDP-glucuronyltransferase, we have to rely more on hypotheses than on facts. This very limited knowledge base on gender specific tumour pharmacology urgently needs to be expanded in randomized clinical trials, because only clinical evidence will provide the sound base necessary for its implementation in oncologic therapies.
This is a preview of subscription content, log in via an institution to check access.
References
Jansman FG, Sleijfer DT, Coenen JL, De Graaf JC, Brouwers JR (2000) Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Drug Saf 23: 255–278
Fazeny-Dorner B, Mader RM, Piribauer M, Rizovski B, Stogermaier B, Marosi C (2004) Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences. Anticancer Drugs 15: 495–498
Milano G, Etienne MC, Cassuto-Viguier E, Thyss A, Santini J, Frenay M, Renee N, Schneider M, Demard F (1992) Influence of sex and age on fluorouracil clearance. J Clin Oncol 10: 1171–1175
Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F, Milano G (1994) Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12: 2248–2253
Diasio RB, Lu Z (1994) Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 12: 2239–2242
Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH (2002) High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12: 555–558
Hsiao HH, Yang MY, Chang JG, Liu YC, Liu TC, Chang CS, Chen TP, Lin SF (2004) Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother Pharmacol 53: 445–451
Mader RM, Schrolnberger C, Rizovski B, Brunner M, Wenzel C, Locker G, Eichler HG, Mueller M, Steger GG (2003) Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. Br J Cancer 88: 782–787
Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM (2004) Pooled analysis of fluorouracilbased adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22: 1797–1806
Meta-Analysis Group In Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16: 3537–3541
Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ (1995) Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 75: 11–17
Mader RM, Steger GG, Rizovski B, Djavanmard MP, Scheithauer W, Jakesz R, Rainer H (1995) Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer. Br J Clin Pharmacol 40: 209–215
Ulrich CM, Robien K, McLeod HL (2003) Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 3: 912–920
Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, Mini E, Boiocchi M (2003) Effect of methylenetetrahydrofolate reductase 677C−>T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 103: 294–299
Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R (2003) Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9: 1611–1615
Lee W, Lockhart AC, Kim RB, Rothenberg ML (2005) Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10: 104–111
Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22: 1382–1388
Beutler E, Gelbart T, Demina A (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95: 8170–8174
Innocenti F, Grimsley C, Das S, Ramirez J, Cheng C, Kuttab-Boulos H, Ratain MJ, Di Rienzo A (2002) Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12: 725–733
Irving JA, Hall AG (2001) Mismatch repair defects as a cause of resistance to cytotoxic drugs. Expert Rev Anticancer Ther 1: 149–158
Dally H, Edler L, Jager B, Schmezer P, Spiegelhalder B, Dienemann H, Drings P, Schulz V, Kayser K, Bartsch H, Risch A (2003) The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics 13: 607–618
Watson MA, Gay L, Stebbings WS, Speakman CT, Bingham SA, Loktionov A (2003) Apolipoprotein E gene polymorphism and colorectal cancer: gender-specific modulation of risk and prognosis. Clin Sci (Lond) 104: 537–545
Oduwole OO, Makinen MJ, Isomaa VV, Pulkka A, Jernvall P, Karttunen TJ, Vihko PT (2003) 17Beta-hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer. J Steroid Biochem Mol Biol 87: 133–140
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mader, R. Gender specific tumour pharmacology – from kinetics to genetics. Wien Med Wochenschr 156, 545–548 (2006). https://doi.org/10.1007/s10354-006-0344-z
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10354-006-0344-z